StockData
MaxCyte, Inc. logo

MaxCyte, Inc. (MXCT) cash flow statement

MXCTNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 9/3062% below fair value
$1.28+0.03 (+2.40%)

Close on Nov 19, 2026Market cap $132.10MP/E –Yield –

MaxCyte, Inc. cash flow statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
79.2%
Operating margin
-134.6%
Net margin
-114.8%
Return on equity, FY2025
-23.6%

Financial strength

Current ratio
12.26
Debt to equity
–
Debt to assets
–
Cash to current liabilities
152.0%

Valuation

P/E ratio
–
Price to sales
4.25
Price to book
0.83
Dividend yield
–

See a number that looks wrong?